Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward

Larenas‐Linnemann, Désirée; Pietropaolo-Cienfuegos, Dino; Calderón, Moisés A.

doi:10.1016/j.anai.2011.07.018

Cited by 27 publications

(23 citation statements)

References 43 publications

(59 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Also, the results of the study by Blumberga et al [15] on house dust mite immunotherapy have shown significant improvement in BHR in 26 patients treated with HDM SCIT in comparison to the 28 patients treated with placebo during the 3 years of follow-up. Desiree et al [16] have assessed the findings from 31 studies on SCIT and concluded that the patients treated with D. pteronyssimus extract experienced 12-fold reduction in specific BHR after only 4-month of treatment compared with no change in the control group (p=0.002). Similar results were obtained in a study by Yukselen et al [17], which included 10 children treated with SCIT, 10 with SLIT and 10 children were on placebo during one year.…”

Section: Discussionmentioning

confidence: 99%

“…In a study by Desiree et al [16], the effects of subcutaneous immunotherapy in Chinese children with asthma have shown that SCIT treatment during 1 year resulted in a reduction of emergency department visits and increase in FEV1 and PEF values. Yekselen et al [17] have studied the effects of SCIT and SLIT in children with rhinitis and asthma during 12 months.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

Luljeta¹,

MehiÄ²,

Gojak³

et al. 2015

Immunome Res

View full text Add to dashboard Cite

Allergen immunotherapy significantly reduced asthma symptoms and medications requirements. Treated patients were significantly less likely to report symptomatic deterioration and less likely to require increased medication. This immunotherapy showed no consistent effect on lung function.The aim of study: In this study, we have determined the difference in the frequency and intensity of bronchial hyper-reactivity in patients with allergic asthma on immunotherapy compared to the patients with allergic asthma receiving only anti-asthmatic pharmacotherapy during one year period of time.Methods: 60 patients were included with allergic asthma, where genders were subsequently divided into two treatment groups. The study group included 30 patients who had received immunotherapy (immunotherapy group) and control group of 30 patients treated with standard pharmacotherapy, but not with immunotherapy (GINA proposal). Each patient in the immunotherapy group was treated with subcutaneous specific immunotherapy (SCIT). The criteria for the inclusion of the patients were clinical diagnosis of allergic asthma, age between 15 and 30 years, and both sexes. The criteria for the exclusion of the patients were the presence of other acute and chronic diseases of respiratory airways, other allergic diseases (skin allergies, nutritive allergies etc.), and acute and chronic diseases of other organic systems.Results: During the 1 st trimester, the median FEV1 values in control group of patients was 60.5% (46.7-78.25%) and following bronchodilators therapy, it was 81% (56-82.2%), which was a significant (p=0.005). In the immunotherapy group, median FEV1 value was 74% (66.0-77.0%) and following bronchodilator therapy it was 84% (76-89.5%), which was a significant increase (p=0.005). During the 2 nd trimester, the median FEV1 value in control group of patients was 75% (50-79.5%) and following bronchodilators therapy it increased up to 84% (66-88.5%) but the difference was not significantly different (p=0.08). In immunotherapy group, median FEV1 value was 78% (75.5-79.0%) and following bronchodilator therapy, it increased to 82% (79.5-83.75%) but the difference was not significant (p=0.066). During the 3rd trimester, the median FEV1 value in control group of patients was 70% (43-75%) and not significantly increased following bronchodilators therapy up to 84% (51-85%) (p=0.08). In experimental (immunotherapy) group, median FEV1 value was 77% (70-79%) and following bronchodilator therapy, it did not significantly change 76% (68-85%) (p=0.273). During the 4 th trimester, the median FEV1 value in control group of patients was 65% (54-75%) and significantly increased following bronchodilators therapy to 79% (55-83%) (p=0.018). In immunotherapy group, median FEV1 value was 79% (68-79.5%) and did not change significantly following bronchodilator therapy 90% (67.5-95.75%)) (p=0.18). Conclusion:In this study, the frequency of bronchial hyper reactivity was not significantly different in patients with allergic asthma treated with immunotherapy ...

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

Luljeta¹,

MehiÄ²,

Gojak³

et al. 2015

Immunome Res

View full text Add to dashboard Cite

show abstract

“…Cochrane reviews included just 2 out of 88 AIT trials with Cladosporium in its meta-analysis [29][30][31]. There has been acceptable evidence showing Alternaria SCIT is beneficial in allergic children and improves medication scores, combined symptom-medication scores, and quality of life in the patients [32]. Some evidence for Alternaria SLIT efficacy is appearing [33].…”

Section: Limitations To Immunotherapymentioning

confidence: 99%

Mold Allergy, Its Prevention and Therapy - Part 2

Özdemir¹

2015

MOJI

View full text Add to dashboard Cite

In the current treatment of mold allergy, there are two modalities: Preventive and therapeutic approaches. Preventive approaches include measurements against indoor as well as outdoor molds. Relative humidity is suggested to maintain at <50% indoor environments. Windows are kept closed in warm months and air-conditioning ought to be used. Indoor plants, as a possible cause of allergen, should be exposed to direct sunlight from time to time.Visible molds are cleaned and mold-infested resources are should be discarded from houses. Washable surfaces must be cleaned with 5% bleach and detergent solution. Damp carpets are ought to dried out quickly and to think taking them away if humidity is not immediately goes away. In bathrooms, curtains and tile should be regularly checked and mended to keep waterproof. Firewood or newspaper piles or old books are regularly scrutinized and thrown away as necessary. Drip pans for fridges, garages and basements at homes should be regularly checked and cleaned. Water leaks in dwellings should be fixed swiftly.In outdoor environment, intense exposure to moldy plants must be avoided. A well-fitted particulate mask when functioning with moldy objects ought to be used. Air-conditioned vehicles should be utilized. Therapeutic approaches mentioned here for fungal allergy is specifically mold allergen immunotherapy in addition to pharmacotherapy against the effects of mold allergy. Mold allergen immunotherapy, as a specific therapy of fungal allergy, is previously hindered by the poor quality of most of the commercial extracts. There have been only several studies evaluating the efficacy of allergen immunotherapy with Alternaria extracts in patients with respiratory mold allergy.A meta-analysis demonstrated that clinical efficacy of allergen immunotherapy with mold extracts was revealed in 79 actively treated cases in 4 controlled trials, with only 2 mold species, namely Alternaria alternate and Cladosporium herbarium. Recently the American Academy of Allergy, Asthma & Immunology concluded that immunotherapy might be effective for mold allergy. In near future, diagnosis and therapy for mold allergy will be more decisive and effective with newly developed production techniques and methods.

show abstract

“…Three of the 23 reviews included only children or adolescents, 16,26,32 and the remainder included both adults and children; some of the reviews had subgroup analyses by age group. Four reviews involved only SCIT, 10 involved only SLIT, and 9 involved both SCIT and SLIT.…”

Section: Review Characteristicsmentioning

confidence: 99%

“…Among children with allergenic rhinitis, 3 reviews reported anaphylaxis or epinephrine use in the SLIT group 22,29,32 (Appendix 7, available at www.cmajopen.ca/content/5/2/ E373/suppl/DC1). It is difficult to judge overlap between these reviews because of the use of confidential manufacturer's reports in 1 review.…”

Section: Childrenmentioning

confidence: 99%

Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review

et al. 2017

View full text Add to dashboard Cite

Evidence of effect of subcutaneous immunotherapy in children: complete and updated review from 2006 onward

Cited by 27 publications

References 43 publications

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

The Frequency and Intensity of Bronchial Hyper-Reactivity in Patients with Allergic Asthma on Immunotherapy

Mold Allergy, Its Prevention and Therapy - Part 2

Allergen immunotherapy for the treatment of allergic rhinitis and/or asthma: an umbrella review

Contact Info

Product

Resources

About